An Exploratory Phase 1/2 Clinical Trial Evaluating ALD518 in Subjects With Glucocorticoid-Refractory Acute Graft vs. Host Disease (GVHD) After Allogeneic Hematopoietic Stem Cell Transplant (HSCT)
Phase of Trial: Phase I/II
Latest Information Update: 25 Apr 2018
At a glance
- Drugs Clazakizumab (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Alder Biopharmaceuticals
- 16 Apr 2018 Status changed from completed to discontinued.
- 01 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.